Equities analysts expect Intrexon Corporation (NYSE:XON) to post earnings of ($0.22) per share for the current quarter, according to Zacks. Four analysts have provided estimates for Intrexon Corporation’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.30). Intrexon Corporation posted earnings per share of ($0.24) in the same quarter last year, which would suggest a positive year over year growth rate of 8.3%. The company is expected to report its next earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that Intrexon Corporation will report full-year earnings of ($0.84) per share for the current year, with EPS estimates ranging from ($0.96) to ($0.55). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.75) to ($0.57). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Intrexon Corporation.

Intrexon Corporation (NYSE:XON) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The business had revenue of $54.40 million during the quarter, compared to the consensus estimate of $57.17 million. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The firm’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.42) EPS.

Several equities analysts recently commented on XON shares. BidaskClub raised shares of Intrexon Corporation from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 15th. Zacks Investment Research cut shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Northland Securities set a $30.00 price objective on shares of Intrexon Corporation and gave the company a “buy” rating in a research note on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $37.60.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/15/analysts-anticipate-intrexon-corporation-xon-to-announce-0-22-earnings-per-share.html.

In related news, Director Dean J. Mitchell bought 5,000 shares of the company’s stock in a transaction on Friday, August 11th. The stock was acquired at an average cost of $18.33 per share, for a total transaction of $91,650.00. Following the completion of the transaction, the director now directly owns 18,103 shares in the company, valued at approximately $331,827.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Randal J. Kirk bought 132,625 shares of the company’s stock in a transaction on Friday, August 11th. The shares were bought at an average price of $18.85 per share, with a total value of $2,499,981.25. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 144,569 shares of company stock valued at $2,719,429. 55.10% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the business. Teachers Advisors LLC lifted its holdings in shares of Intrexon Corporation by 6.4% in the 4th quarter. Teachers Advisors LLC now owns 50,172 shares of the biotechnology company’s stock worth $1,219,000 after acquiring an additional 3,005 shares during the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of Intrexon Corporation by 10.1% in the 1st quarter. Advisors Asset Management Inc. now owns 31,900 shares of the biotechnology company’s stock worth $632,000 after acquiring an additional 2,922 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Intrexon Corporation by 16.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 24,240 shares of the biotechnology company’s stock worth $480,000 after acquiring an additional 3,400 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Intrexon Corporation by 2.2% in the 1st quarter. Swiss National Bank now owns 97,700 shares of the biotechnology company’s stock worth $1,936,000 after acquiring an additional 2,100 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its holdings in shares of Intrexon Corporation by 16.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 33,333 shares of the biotechnology company’s stock worth $661,000 after acquiring an additional 4,773 shares during the last quarter. Institutional investors and hedge funds own 82.27% of the company’s stock.

Shares of Intrexon Corporation (NYSE:XON) traded up 2.54% during trading on Friday, reaching $19.37. 1,505,797 shares of the company traded hands. Intrexon Corporation has a 12-month low of $17.03 and a 12-month high of $32.90. The firm’s 50-day moving average is $19.65 and its 200-day moving average is $21.44. The stock’s market capitalization is $2.33 billion.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Get a free copy of the Zacks research report on Intrexon Corporation (XON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.